These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 4087171)

  • 1. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.
    Gillespie WR; Veng-Pedersen P
    J Pharmacokinet Biopharm; 1985 Aug; 13(4):441-51. PubMed ID: 4087171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis.
    Veng-Pedersen P
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):627-48. PubMed ID: 6533297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single pass mean residence time in peripheral tissues: a distribution parameter intrinsic to the tissue affinity of a drug.
    Veng-Pedersen P; Gillespie WR
    J Pharm Sci; 1986 Dec; 75(12):1119-26. PubMed ID: 3559920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. IV. Exact relationship between the terminal log-linear slope parameter beta and drug clearance.
    Veng-Pedersen P; Gillespie WR
    J Pharmacokinet Biopharm; 1987 Jun; 15(3):305-25. PubMed ID: 3668806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.
    Veng-Pedersen P; Gillespie WR
    J Pharmacokinet Biopharm; 1987 Jun; 15(3):281-304. PubMed ID: 3668805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel method of calculating absolute bioavailability in nonlinear pharmacokinetics.
    Veng-Pedersen P
    J Pharm Sci; 1985 Jan; 74(1):90-3. PubMed ID: 3981428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution Clearance: Significance and Underlying Mechanisms.
    Weiss M
    Pharm Res; 2024 Jul; 41(7):1391-1400. PubMed ID: 38981900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body.
    Berezhkovskiy LM
    J Pharm Sci; 2013 Feb; 102(2):761-71. PubMed ID: 23233148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance.
    Gibaldi M; Koup JR
    Eur J Clin Pharmacol; 1981; 20(4):299-305. PubMed ID: 7308282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug absorption evaluation in the presence of changes in clearance: an algorithm and computer program for deconvolution with exact clearance correction.
    Veng-Pedersen P
    Biopharm Drug Dispos; 1987; 8(2):185-203. PubMed ID: 3593898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.
    Cheng HY; Jusko WJ
    Pharm Res; 1991 Apr; 8(4):508-11. PubMed ID: 1871048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans.
    Veng-Pedersen P; Widness JA; Pereira LM; Peters C; Schmidt RL; Lowe LS
    J Pharm Sci; 1995 Jun; 84(6):760-7. PubMed ID: 7562419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nonlinear physiologic pharmacokinetic model: I. Steady-state.
    Wagner JG; Szpunar GJ; Ferry JJ
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):73-92. PubMed ID: 4020623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug dosage in renal disease.
    Dettli L
    Clin Pharmacokinet; 1976; 1(2):126-34. PubMed ID: 797495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):834-48. PubMed ID: 16493592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model independent derivation of general equations for the "first-pass" effect and extra-hepatic drug elimination.
    Vaughan
    Eur J Clin Pharmacol; 1977; 11(1):57-64. PubMed ID: 832659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moments of physiological transit time distributions and the time course of drug disposition in the body.
    Weiss M
    J Math Biol; 1982; 15(3):305-18. PubMed ID: 7153675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Criticism of pharmacokinetic clearance concepts.
    Keller F; Schoole J
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):563-8. PubMed ID: 6654532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.